Acceleron Pharma, Inc. (XLRN) – Sotatercept

Forecasting Dashboard

< Return to POC2 drug list



Please add insights, questions and comments here and respond to others’ questions / comments.

You can also see the comments your peers have submitted in their initial assessments in the “Forecasting and relevant links” tab.

Please do not disclose information about your identity or reference years/types of expertise. Those actions contribute to authority bias and decrease the predictive power of collective intelligence.

If you press the subscribe button, next to the email icon below, you can receive an email alert when people post in this drug’s discussion.

3 2 votes
How valuable was the briefing?
Notify of
Oldest Most Voted
Inline Feedbacks
View all comments

Recognizing that many of the historical (SOC) agents have been approved for use based on 6-minute walk as a primary, is it concerning that the current trial has demoted 6MW to a secondary? Curious also if other indications are planned down the road, like CTEPH…

Sotatercept was first used to modulate TGFb signaling associated with erythropoesis (thru 2015) and was replaced by luspatercept – which went on to be approved. Seems they pivoted to hypothesis for PAH, which is preclinically well founded in nice work highlighted here:

preclinical data suggests this approach is superior to use of PDE5 inhibitors (sildenafil, tadalafil) which have gained common use alone or in combination with vasodilator or endothelin receptor antagonist.

Forecasting and relevant links

Forecaster Actions

Click to answer the Acceleron-Sotatercept Follow-up Questions

Please answer those questions by Tuesday evening, January 5.


Here are what everyone submitted initially:   Summary of Initial Asssessments



Initial Assessment

Supporting Materials

Acceleron Website